Log in
NASDAQ:MRTX

Mirati Therapeutics Stock Forecast, Price & News

$167.27
+6.24 (+3.88 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$158.06
Now: $167.27
$167.51
50-Day Range
$125.81
MA: $143.86
$163.79
52-Week Range
$66.01
Now: $167.27
$171.48
Volume332,725 shs
Average Volume512,973 shs
Market Capitalization$7.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More
Mirati Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.34 million
Book Value$9.67 per share

Profitability

Net Income$-213,260,000.00
Net Margins-10,983.84%

Miscellaneous

Employees63
Market Cap$7.45 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$167.27
+6.24 (+3.88 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

How has Mirati Therapeutics' stock price been impacted by COVID-19?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRTX stock has increased by 116.2% and is now trading at $167.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mirati Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mirati Therapeutics
.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Mirati Therapeutics
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.10) by $0.21. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 57.01%.
View Mirati Therapeutics' earnings history
.

What price target have analysts set for MRTX?

12 brokerages have issued twelve-month price objectives for Mirati Therapeutics' shares. Their forecasts range from $85.00 to $190.00. On average, they expect Mirati Therapeutics' stock price to reach $144.73 in the next twelve months. This suggests that the stock has a possible downside of 13.5%.
View analysts' price targets for Mirati Therapeutics
.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), QUALCOMM (QCOM), Square (SQ), Alibaba Group (BABA), Docusign (DOCU) and Gilead Sciences (GILD).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.74%), Perceptive Advisors LLC (6.22%), FMR LLC (4.65%), Orbimed Advisors LLC (2.97%), RTW Investments LP (2.44%) and Jennison Associates LLC (1.16%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Michael G Grey and Venbio Select Advisor Llc.
View institutional ownership trends for Mirati Therapeutics
.

Which institutional investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, FMR LLC, Perceptive Advisors LLC, Orbimed Advisors LLC, Jennison Associates LLC, Holocene Advisors LP, Bluefin Trading LLC, and Deerfield Management Company L.P. Series C. Company insiders that have sold Mirati Therapeutics company stock in the last year include Bruce L A Carter, Charles M Baum, Craig A Johnson, Henry J Fuchs, Isan Chen, Ltd Braslyn, and Michael G Grey.
View insider buying and selling activity for Mirati Therapeutics
.

Which institutional investors are buying Mirati Therapeutics stock?

MRTX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Federated Hermes Inc., RTW Investments LP, Assenagon Asset Management S.A., Man Group plc, Vanguard Group Inc., Charles Schwab Investment Management Inc., and Edmond DE Rothschild Holding S.A..
View insider buying and selling activity for Mirati Therapeutics
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $167.27.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $7.45 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.